We are live on ! Find out more
SCNI

Scinai Immunotherapeutics
SCNI

11 hedge funds and large institutions have $49.1K invested in Scinai Immunotherapeutics in 2026 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

230% more capital invested

Capital invested by funds: $14.9K → $49.1K (+$34.2K)

175% more funds holding

Funds holding: 4 → 11 (+7)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0.4% more ownership

Funds ownership: 0.08% → 0.48% (+0.4%)

Holders
11
Holders Change
+7
Holders Change %
+175%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
2
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$30.6K
2
AC
Armistice Capital
New York
+$17.7K
3
VF
Virtu Financial
New York
+$9.58K
4
SG
StoneX Group
New York
+$6.44K
5
HF
HRT Financial
New York
+$5.95K

Top Sellers

Rank Fund Capital Flow
1
XT
XTX Topco
Cayman Islands
-$3.58K

SCNI Hedge Fund Activity: Q2 2026 in Review

11 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q2 2026, worth a combined $49.1K — up 230% from $14.9K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new SCNI positions and 0 closed out — a net gain of 7 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $30.6K. The largest seller was XTX Topco, cutting an estimated $3.58K.

  • 11 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q2 2026, up from 4 in Q1 2026.
  • Funds reported $49.1K of Scinai Immunotherapeutics stock for Q2 2026, up 230% quarter-over-quarter.
  • 7 funds opened new Scinai Immunotherapeutics positions in Q2 2026 and 0 closed out, a net change of +7 holders.
  • The largest Scinai Immunotherapeutics buyer in Q2 2026 was Citadel Advisors, an estimated $30.6K added.
  • The largest Scinai Immunotherapeutics seller in Q2 2026 was XTX Topco, an estimated $3.58K sold.

Based on aggregated 13F filings for Q2 2026.